Safety and efficacy of the XIENCE V everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice. (Record no. 1397)

MARC details
000 -LEADER
fixed length control field 04546nam a22006737a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 130913s20122012 xxu||||| |||| 00| 0 eng dOvid Technologies
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 0002-9149
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 22341925
245 ## - TITLE STATEMENT
Title Safety and efficacy of the XIENCE V everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice.
251 ## - Source
Source American Journal of Cardiology. 109(9):1288-94, 2012 May 1.
252 ## - Abbreviated Source
Abbreviated source Am J Cardiol. 109(9):1288-94, 2012 May 1.
253 ## - Journal Name
Journal name The American journal of cardiology
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2012
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2012
266 ## - Date added to catalog
Date added to catalog 2013-09-17
501 ## - WITH NOTE
Local holdings Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006
520 ## - SUMMARY, ETC.
Abstract Data from randomized clinical trials have shown the safety and efficacy of the XIENCE V in selected populations. However, limited data are available comparing the XIENCE V to the first-generation CYPHER sirolimus-eluting stent. This study aimed to assess the long-term safety and clinical efficacy of the XIENCE V everolimus-eluting stent compared to first-generation stents in an unselected patient population. This retrospective analysis included 6,069 patients treated with CYPHER, TAXUS, and XIENCE stents from 2003 to 2009 at our institution. The patients were followed up for >=1 year after the index procedure. The baseline characteristics were generally comparable among the 3 groups, with the exception of a significantly greater prevalence of diabetes mellitus, systemic hypertension, and a history of angioplasty and coronary bypass surgery among the XIENCE patients. The XIENCE patients also had a twofold greater rate of type C lesions. One-year follow-up data were available for 82% of the patients. The 1-year major adverse cardiovascular events rate was 9.3% for the XIENCE stent versus 9.8% for the CYPHER stent and 11.5% for the TAXUS stent (p = 0.11). Mortality was lower in the XIENCE group than in the CYPHER and TAXUS groups (3.6% vs 4.9% vs 7.2%, respectively, p <0.001), and target lesion revascularization was similar (5.9% vs 5.2% vs 5.6%, respectively; p = 0.34). Stent thrombosis was lower in the XIENCE patients (0.2% vs 1.2% vs 0.7%, p = 0.007). In conclusion, in a contemporary United States clinical practice with an unselected patient population, use of the XIENCE V stent was associated with an improved safety profile and reduction of all-cause mortality and stent thrombosis compared to first-generation drug-eluting stents. The XIENCE V failed to demonstrate superiority for overall major adverse cardiovascular events, Q-wave myocardial infarction, and revascularization rates. Copyright 2012 Elsevier Inc. All rights reserved.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Angioplasty, Balloon, Coronary/mt [Methods]
9 (RLIN) 952
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Coronary Artery Disease/th [Therapy]
9 (RLIN) 171
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Drug-Eluting Stents
9 (RLIN) 525
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Sirolimus/aa [Analogs & Derivatives]
9 (RLIN) 674
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aged
9 (RLIN) 2
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antineoplastic Agents, Phytogenic/pd [Pharmacology]
9 (RLIN) 966
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Coronary Angiography
9 (RLIN) 90
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Coronary Artery Disease/ra [Radiography]
9 (RLIN) 91
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Coronary Restenosis/pc [Prevention & Control]
9 (RLIN) 967
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Female
9 (RLIN) 7
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Follow-Up Studies
9 (RLIN) 968
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
9 (RLIN) 11
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Immunosuppressive Agents/pd [Pharmacology]
9 (RLIN) 969
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Male
9 (RLIN) 14
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Middle Aged
9 (RLIN) 15
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Paclitaxel
9 (RLIN) 970
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Prosthesis Design
9 (RLIN) 81
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Retrospective Studies
9 (RLIN) 46
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Sirolimus/pd [Pharmacology]
9 (RLIN) 971
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Treatment Outcome
9 (RLIN) 18
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Heart & Vascular Institute
657 ## - INDEX TERM--FUNCTION
Medline publication type Comparative Study
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
657 ## - INDEX TERM--FUNCTION
Medline publication type Randomized Controlled Trial
657 ## - INDEX TERM--FUNCTION
Medline publication type Research Support, Non-U.S. Gov't
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Barbash, Israel M
9 (RLIN) 965
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Ben-Dor, Itsik
9 (RLIN) 22
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Dvir, Danny
9 (RLIN) 23
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Kent, Kenneth M
9 (RLIN) 135
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Maluenda, Gabriel
9 (RLIN) 286
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Pichard, Augusto D
9 (RLIN) 27
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Satler, Lowell F
9 (RLIN) 29
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Suddath, William O
9 (RLIN) 139
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Torguson, Rebecca
9 (RLIN) 140
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Waksman, Ron
9 (RLIN) 30
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Xue, Zhenyi
9 (RLIN) 141
790 ## - Authors
All authors Barbash IM, Ben-Dor I, Dvir D, Kent KM, Maluenda G, Pichard AD, Satler LF, Suddath WO, Torguson R, Waksman R, Xue Z
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="http://dx.doi.org/10.1016/j.amjcard.2011.12.019">http://dx.doi.org/10.1016/j.amjcard.2011.12.019</a>
Public note http://dx.doi.org/10.1016/j.amjcard.2011.12.019
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Source of classification or shelving scheme Other/Generic Classification Scheme
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 09/17/2013   22341925 22341925 09/17/2013 09/17/2013 Journal Article

Powered by Koha